Large study finds no evidence cannabis treats anxiety, depression or PTSD

A major review published in The Lancet Psychiatry concludes that medicinal cannabis does not effectively treat anxiety, depression or post-traumatic stress disorder. The analysis of 54 randomized controlled trials over 45 years found limited evidence for other conditions like insomnia and autism. Researchers warn of potential harms including psychosis risk and delayed effective treatments.

The largest review to date on cannabinoids for mental health conditions, published in The Lancet Psychiatry, reports no effective treatment for anxiety, depression or PTSD. Led by Dr. Jack Wilson from the University of Sydney's Matilda Centre, the study examined safety and effectiveness across various disorders using data from 54 randomized controlled trials spanning 1980 to 2025. About 27 percent of people aged 16-65 in the United States and Canada report medical cannabis use, with half citing mental health symptoms as the reason. Dr. Wilson stated, 'Though our paper didn't specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments.' Limited indications of benefit appeared for cannabis use disorder, autism, insomnia and tics or Tourette's syndrome, though evidence quality remains low. Dr. Wilson noted, 'In the absence of robust medical or counseling support, the use of medicinal cannabis in these cases are rarely justified.' For substance use disorders, cannabis-based treatments showed potential for cannabis dependence when combined with psychological therapy, but increased cravings in cocaine-use disorder cases. The review confirms benefits for epilepsy-related seizures, multiple sclerosis spasticity and certain pain types, but not mental health. Funded by the NHMRC, the findings support evidence-based clinical decisions amid rising medicinal cannabis use and calls for stricter regulation from groups like the American Medical Association.

ተያያዥ ጽሁፎች

PET brain scan revealing AMPA receptor changes linked to ketamine's antidepressant effects in treatment-resistant depression study.
በ AI የተሰራ ምስል

PET brain scans link ketamine’s rapid antidepressant effect to shifts in AMPA receptor availability

በAI የተዘገበ በ AI የተሰራ ምስል እውነት ተፈትሸ

A study in Molecular Psychiatry used PET imaging with a new tracer to track changes in AMPA-type glutamate receptors in people with treatment-resistant depression receiving ketamine, reporting that region-specific receptor changes were associated with symptom improvement.

A new study from Washington State University shows that consuming THC leads to false memories and disrupts various everyday memory functions. Participants who used cannabis recalled nonexistent words and struggled with tasks like remembering future actions. The research highlights effects even at moderate doses.

በAI የተዘገበ

A new review of clinical trials suggests that psychedelics like psilocybin are effective for treating depression but offer no advantage over traditional antidepressants. Researchers accounted for the challenge of blinding in psychedelic studies, where participants can often tell if they received the drug. The findings indicate similar outcomes when compared to unblinded antidepressant trials.

Researchers at Stellenbosch University say they have found the first evidence of rare phenolic compounds known as flavoalkaloids in cannabis leaves, after profiling dozens of plant chemicals across three commercially grown strains.

ይህ ድረ-ገጽ ኩኪዎችን ይጠቀማል

የእኛን ጣቢያ ለማሻሻል ለትንታኔ ኩኪዎችን እንጠቀማለን። የእኛን የሚስጥር ፖሊሲ አንብቡ የሚስጥር ፖሊሲ ለተጨማሪ መረጃ።
ውድቅ አድርግ